D. Oscier

发表

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.

G. Morgan, D. Catovsky, D. Gonzalez, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1.

Dan Grandér, David Oscier, J. Lovén, 2009, Experimental cell research.

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

Andrew Collins, Andrew Chase, Nicholas C P Cross, 2009, Nature Genetics.

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.

Adrian Wiestner, Sarah E Henrickson, Gerald E Marti, 2003, Blood.

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

Adrian Wiestner, Andreas Rosenwald, L. Staudt, 2004, The Lancet.

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

H. Drexler, D. Oscier, A. Jones, 2010, Nature Genetics.

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

D. Oscier, M. Cragg, A. Vaughan, 2011, Blood.

An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors

D. Tzovaras, K. Stamatopoulos, M. Piris, 2015, Clinical Cancer Research.

Splenic B-Cell Lymphoma Group splenic marginal zone B-cell lymphomas: a multicenter study of the Cytogenetic aberrations and their prognostic value in a series of 330

A. Salar, F. Berger, S. Serrano, 2011 .

Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group.

A. Salar, F. Berger, S. Serrano, 2010, Blood.

Splenic marginal zone lymphoma.

D. Oscier, R. Owen, S. Johnson, 2005, Blood reviews.

Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.

F. Berger, K. Stamatopoulos, N. Darzentas, 2012, Leukemia.

Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.

Lefteris Angelis, Véronique Giudicelli, Marco Montillo, 2014, The Lancet. Haematology.

Selection of antigen receptors in splenic marginal-zone lymphoma: further support from the analysis of the immunoglobulin light-chain gene repertoire

F. Berger, K. Stamatopoulos, N. Darzentas, 2012, Leukemia.

Splenic lymphoma with villous lymphocytes involves B cells with extensively mutated Ig heavy chain variable region genes.

D. Oscier, D. Zhu, F. Stevenson, 1995, Blood.

V(H) gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo.

D. Oscier, J. Orchard, D. Wright, 2002, Blood.

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.

Kostas Stamatopoulos, Xavier Brochet, Nikolaos Laoutaris, 2012, Blood.

Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants

T. Stankovic, G. Stewart, P. Moss, 2015, Haematologica.

DETECTION OF RETROVIRUS IN PATIENTS WITH MYELOPROLIFERATIVE DISEASE

D. Oscier, N. Maclean, M. Boyd, 1989, The Lancet.

High‐throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal‐zone lymphoma

J. Martinez-Climent, E. Vizcarra, F. Prósper, 2012, British journal of haematology.

Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis.

A. Green, D. Oscier, M. McMullin, 2008, Blood.

Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay

D. Oscier, J. Orchard, A. G. Bosanquet, 1999, British journal of haematology.

Cytogenetic and molecular abnormalities in chronic lymphocytic leukaemia.

D. Oscier, 1994, Blood reviews.

Immunological abnormalities in myelodysplastic syndromes I. SERUM IMMUNOGLOBULINS AND AUTOANTIBODIES

G. Mufti, D. Oscier, T. Hamblin, 1986, British journal of haematology.

Comparative sequence analysis of a region on human chromosome 13q14, frequently deleted in B-cell chronic lymphocytic leukemia, and its homologous region on mouse chromosome 14.

E. Zabarovsky, A. Baranova, G. Gahrton, 2000, Genomics.

Title: Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project

Stephen, E. Montserrat, N. Villamor, 2017 .

Ha-ras hypervariable alleles in myelodysplasia

J. Flint, D. Oscier, S. Thein, 1986, Nature.

Prognostic factors in stage AO B‐cell chronic lymphocytic leukaemia

D. Oscier, R. Pickering, T. Hamblin, 1990, British journal of haematology.

CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.

M. Dyer, C. Fegan, R. Hills, 2011, Leukemia research.

Guidelines for the diagnosis and management of acquired aplastic anaemia

D. Oscier, S. Ball, E. Gordon-Smith, 2003, British journal of haematology.

Dyskeratosis congenita fibroblasts are abnormal and have unbalanced chromosomal rearrangements.

L. Luzzatto, D. Oscier, I. Dokal, 1992, Blood.

DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome.

J. Ihle, D. Oscier, V. Buckle, 1994, Blood.

A Systematic Search Into The Role Of IGHV Gene Replacement In Shaping The Immunoglobulin Repertoire Of Chronic Lymphocytic Leukemia

Wentian Li, K. Stamatopoulos, Xiao-Jie Yan, 2013 .

A new minimal deleted region at 11q22.3 reveals the importance of interpretation of diminished FISH signals and the choice of probe for ATM deletion screening in chronic lymphocytic leukemia.

T. Stankovic, D. Oscier, J. Strefford, 2012, Leukemia research.

Karyotypic evolution in B‐cell chronic lymphocytic leukaemia

D. Oscier, M. Fitchett, T. Herbert, 1991, Genes, chromosomes & cancer.

13q Deletion Size Predicts Disease Progression and Response to Treatment in Patients with Chronic Lymphocytic Leukaemia.

D. Oscier, B. Young, J. Strefford, 2009 .

ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial

T. Stankovic, D. Catovsky, D. Oscier, 2014, Haematologica.

ZAP-70 in B cell malignancies

D. Oscier, R. Ibbotson, J. Orchard, 2005, Leukemia & lymphoma.

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

J. Gribben, A. Pettitt, G. Follows, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia

A. Pettitt, C. Fegan, G. Follows, 2012, British journal of haematology.

Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.

Li Wang, Luca Malcovati, Mario Cazzola, 2006, Blood.

imatinib or interferon alpha Minimal molecular response in polycythemia vera patients treated with

D. Oscier, A. Jones, A. Chase, 2011 .

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.

D. Oscier, A. Jones, A. Chase, 2005, Blood.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

Paola Guglielmelli, Torsten Haferlach, William Tapper, 2015, Nature Communications.

Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation

A. Salar, F. Solé, I. Varela, 2014, Leukemia.

ras Mutations in the Myelodysplastic Syndromes

D. Oscier, D. Bowen, A. Jacobs, 1992 .

Ras Mutations in Primary Myelodysplasia and in Patients Following Cytotoxic Therapy

D. Oscier, R. Clark, D. Bowen, 1989 .

RAS mutations in preleukaemias.

F. McCormick, D. Oscier, A. Jacobs, 1989, Haematology and blood transfusion.

Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia

E. Zabarovsky, G. Gahrton, G. Juliusson, 1997, Oncogene.

IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL)

D. Catovsky, E. Matutes, D. Oscier, 2006, Leukemia.

Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.

U. Jaeger, D. Oscier, V. Leblond, 2005, Clinical lymphoma.

Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis

P. Campbell, T. Pearson, M. Polkey, 2005, British journal of haematology.

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

I. Vlahavas, E. Campo, H. Döhner, 2017, Clinical Cancer Research.

The management of ‘low‐risk’ and ‘intermediate‐risk’ patients with primary thrombocythaemia

D. Oscier, J. Reilly, M. McMullin, 1999, British journal of haematology.

FOR THE DIAGNOSIS , INVESTIGATION AND MANAGEMENT OF POLYCYTHAEMIA / ERYTHROCYTOSIS Writing Group

Wilkins, P. Campbell, M. Polkey, 2005 .

Splenic Lymphoma With Villous Lymphocytes: Analysis

M. Dyer, D. Catovsky, D. Oscier, 2002 .

Splenic lymphoma with villous lymphocytes: analysis of BCL-1 rearrangements and expression of the cyclin D1 gene.

D. Catovsky, D. Oscier, E. Matutes, 1994, Blood.

FMS mutations in myelodysplastic, leukemic, and normal subjects.

M. Worwood, D. Oscier, S. Ridge, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Identification of four new translocations involving FGFR1 in myeloid disorders

G. Martinelli, D. Oscier, M. Corcoran, 2001, Genes, chromosomes & cancer.

Autoimmunity in chronic lymphocytic leukaemia.

D. Oscier, T. Hamblin, B. Young, 1986, Journal of clinical pathology.

Lymphoid neoplasms.

D. Oscier, A. Gardiner, 2001, Baillière's Best Practice & Research: Clinical Haematology.

Guidelines on the management of Waldenström macroglobulinaemia *

D. Oscier, R. Owen, S. Johnson, 2006, British journal of haematology.

Capillary electrophoresis‐laser induced fluorescence analysis of endogenous damage in mitochondrial and genomic DNA

D. Oscier, O. Schmitz, Michael C. Wirtz, 2005, Electrophoresis.

Over‐expression of the MDM2 gene is found in some cases of haematological malignancies

B. Quesnel, D. Oscier, C. Preudhomme, 1994, British journal of haematology.

Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.

M. Dyer, T. Stankovic, P. Moss, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TheBCL11gene family: involvement of BCL11Ain lymphoid malignancies

D. Steinemann, R. Siebert, M. Dyer, 2001 .

Telomere length in myelodysplastic syndromes

R. Kusec, D. Oscier, J. Boultwood, 1995, American journal of hematology.

Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma.

A. López-Guillermo, F. Cavalli, A. Elia, 2021, Blood.

Divergence from the germ-line sequence in unmutated chronic lymphocytic leukemia is due to somatic mutation rather than polymorphisms.

D. Oscier, Z. Davis, M. Corcoran, 2003, Blood.

internalization and reduces clinical efficacy Fc gamma receptor IIb on target B cells promotes rituximab

D. Oscier, M. Cragg, A. Vaughan, 2012 .

Guidelines on the diagnosis and management of chronic lymphocytic leukaemia

C. Fegan, P. Maguire, D. Oscier, 2004, British journal of haematology.

Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study

E. Campo, A. Enjuanes, K. Stamatopoulos, 2020, Haematologica.

Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.

A. Pettitt, C. Plass, R. Rosenquist, 2019, Blood advances.

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

E. Campo, N. Villamor, J. Delgado, 2018, Haematologica.

TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype

M. Salido, S. Beà, T. Baumann, 2022, Cancers.

The Clinical Presentation of CLL

D. Catovsky, D. Oscier, M. Else, 2019, Hematologic Malignancies.

Guidelines for Manufacturers’manuals for use in developing countries

D. Oscier, T. Hamblin, T. Hamblin, 1987 .

Molecular definition of a narrow interval at 7q22.1 associated with myelodysplasia.

S. Scherer, L. Tsui, D. Oscier, 1996, Blood.

Establishing the incidence of myelodysplastic syndrome

D. Oscier, T. Hamblin, A. Kruger, 1994 .

Myelodysplastic syndromes.

D. Oscier, 2007, Bailliere's clinical haematology.

The Optimal Management of Polycythaemia Vera

D. Oscier, J. Reilly, M. McMullin, 2003, British journal of haematology.

University of Birmingham MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia

R. Greil, E. Montserrat, H. Döhner, 2014 .

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.

C. Fegan, D. Oscier, A. Rawstron, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Pilot Study of Idiotypic Vaccination for Follicular B-cell Lymphoma Using a Genetic Approach. University of Bristol, Bristol, United Kingdom

N. Bleehen, G. Winter, S. Russell, 1997 .

A phase I trial of the PARP inhibitor olaparib in patients with relapsed or refractory Chronic Lymphocytic Leukaemia, T-Prolymphocytic Leukaemia or Mantle Cell Lymphoma

A. Pettitt, M. Dyer, T. Stankovic, 2018 .

Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

R. Siebert, M. Dyer, T. Stankovic, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peripheral blood stem cell autografting

D. Oscier, T. Hamblin, A. Bell, 1987, Hematological oncology.

Use of circulating stem cells to accelerate myeloid recovery after autologous bone marrow transplantation.

D. Oscier, T. Hamblin, A. Figes, 1987, British journal of haematology.

Circulating stem cell autografts.

D. Oscier, T. Hamblin, A. J. Bell, 1986, Bone marrow transplantation.

CD3+ CD8+ T cell lymphocytosis masking B cell leukaemia.

D. Oscier, T. Hamblin, D. Jones, 1988, Journal of clinical pathology.

CD3+ CD8+ Tcell lymphocytosis masking Bcell leukaemia

D. Oscier, F. Stevenson, M. Howell, 1988 .

Splenic marginal zone lymphoma: 7q abnormalities.

D. Oscier, R. Ibbotson, A. Parker, 2005, Methods in molecular medicine.

ZAP‐70 by flow cytometry: A comparison of different antibodies, anticoagulants, and methods of analysis

D. Oscier, Z. Davis, O. G. Best, 2006, Cytometry. Part B, Clinical cytometry.

Establishing the incidence of myelodysplastic syndrome.

D. Oscier, T. Hamblin, A. Kruger, 1994, British journal of haematology.

Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations

K. Stamatopoulos, C. Haferlach, A. Kater, 2022, HemaSphere.

Translocation t(2;7)(p11.2;q21.2): a rare genetic aberration associated with B-cell lymphoproliferative disorders of marginal-zone origin.

F. Solé, M. Salido, K. Stamatopoulos, 2014, Cancer genetics.

Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group.

E. Estey, P. Greenberg, C. Willman, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Translocation t(11; 14)(q 13;q32) in chronic lymphoid disorders

K. Maclennan, D. Catovsky, E. Matutes, 1992, Genes, chromosomes & cancer.

A Randomized Trial of Hydroxyurea Versus VP 16 in Adult Chronic Myelomonocytic Leukemia

B. Pégourié, G. Mufti, D. Oscier, 2022 .

Appelbaum FR, Rowe JM, Radich J, Dick JE. Acute Myeloid Leukemia. Hematology Am Soc Hematol Educ Program. 2001:62-86. PMID: 11722979

E. Campo, P. Greenberg, J. Bennett, 2008 .

Myelodysplastic syndrome with karyotype abnormality is associated with elevated F‐cell production

D. Oscier, J. Craig, M. Contreras, 1996, British journal of haematology.

Low doses of cytarabine in the treatment of myelodysplastic syndrome and acute myeloid leukemia.

G. Mufti, D. Oscier, T. Hamblin, 1983, The New England journal of medicine.

Assessment of fl udarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

D. Catovsky, D. Oscier, E. Matutes, 2007 .

VERY-LOW-DOSE CYTARABINE FOR MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKAEMIA IN THE ELDERLY

G. Mufti, D. Oscier, T. Hamblin, 1986, The Lancet.

Correlation of bone marrow colony growth in the myelodysplastic syndromes with the FAB classification and the Bournemouth score.

D. Oscier, T. Hamblin, J. Williams, 1989, Leukemia research.

Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients

D. Catovsky, E. Matutes, D. Oscier, 1996, British journal of haematology.

Atypical chronic myeloid leukaemia, a distinct clinical entitity related to the myelodysplastic syndrome?

D. Oscier, 1996, British journal of haematology.

TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKAEMIA WITH LOW DOSE ETOPOSIDE

G. Mufti, D. Oscier, T. Hamblin, 1989, British journal of haematology.

Syndromes International Scoring System for Evaluating Prognosis in Myelodysplastic

G. Mufti, P. Greenberg, J. Bennett, 2010 .

D. Oscier, J. Orchard, T. Hamblin, 1995, British journal of haematology.

Evolution of a terminal deoxynucleotidyl transferase-positive lymphoma from a chronic T cell lymphocytosis.

G. Mufti, D. Oscier, T. Hamblin, 2009, Scandinavian journal of haematology.

Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events.

D. Oscier, T. Hamblin, C. Ottensmeier, 2002, Blood.

Unmutated immunoglobulin VH genes are associated with a more aggressive form of chronic lymphocyte leukemia

D. Oscier, Z. Davis, T. Hamblin, 1999 .

Assessment of fl udarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

D. Catovsky, D. Oscier, E. Matutes, 2007 .

Structural abnormalities of chromosome 7q in chronic lymphoproliferative disorders.

D. Oscier, A. Gardiner, S. Mould, 1996, Cancer genetics and cytogenetics.

LYMPHOID NEOPLASIA DNA methylation pro ﬁ ling identi ﬁ es two splenic marginal zone lymphoma subgroups with different clinical and genetic features

J. Martinez-Climent, L. Cascione, M. Piris, 2015 .

CBL-MZ is not a single biological entity: evidence from genomic analysis and prolonged clinical follow-up.

D. Oscier, Z. Davis, M. Rose-Zerilli, 2018, Blood advances.

Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: A systematic reappraisal of classic cytogenetic data

K. Stamatopoulos, Š. Pospíšilová, D. Oscier, 2014, American journal of hematology.

PERIPHERAL BLOOD STEM CELL AUTOGRAFTING

D. Oscier, T. Hamblin, A. Figes, 1986, The Lancet.

CYTARABINE IN PRE-LEUKAEMIA

D. Oscier, T. Hamblin, A. Copplestone, 1984, The Lancet.

Response to Drs Jones and Brodsky

D. Oscier, S. Ball, E. Gordon-Smith, 2004 .

Circulating micromegakaryocytes in myelodysplasia.

W. Erber, D. Oscier, D. Mason, 1987, Journal of clinical pathology.

Clonality of cell populations in refractory anaemia using combined approach of gene loss and X‐linked restriction fragment length polymorphism‐methylation analyses

D. Oscier, V. Buckle, J. Boultwood, 1991, British journal of haematology.

Loss of both CSFIR ( FMS ) alleles in patients with myelodysplasia and a chromosome 5 deletion ( hematopoietic growth factors / myeloid leukemias / colony-stimulating factor 1 receptor / c-fins gene )

D. Oscier, J. Boultwood, J. Wainscoat, 2022 .

COEXISTENT LYMPHOID OR PLASMA CELL NEOPLASMS

G. Mufti, D. Oscier, T. Hamblin, 1987, British journal of haematology.

Comparison of cytogenetic and restriction fragment length polymorphism analyses for the detection of loss of chromosome material in clonal hemopoietic disorders

D. Oscier, V. Buckle, J. Wainscoat, 1993, American journal of hematology.

Genomic organization of a tumor growth inhibitor geneING1

D. Oscier, M. Corcoran, N. Makeeva, 2000, Molecular Biology.

ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele

M. Dyer, T. Stankovic, C. Fegan, 2012, Haematologica.

IN PATIENTS WITH LYMPHOID TUMOURS RECOVERING FROM THE AUTOIMMUNE COMPLICATIONS OF FLUDARABINE, RELAPSE MAY BE TRIGGERED BY CONVENTIONAL CHEMOTHERAPY

D. Oscier, J. Orchard, T. Hamblin, 1998, British journal of haematology.

Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia

Emanuela M. Ghia, Wentian Li, J. Byrd, 2022, Frontiers in Oncology.

Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia

I. Vlahavas, K. Stamatopoulos, I. Chouvarda, 2014, Immunogenetics.

Prognostic markers in chronic lymphocytic leukemia

D. Oscier, M. Keating, C. Tam, 2012 .

P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12

D. Oscier, L. Zhang, A. Chase, 2003, Leukemia.

ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres

K. Stamatopoulos, G. Juliusson, R. Rosenquist, 2016, Haematologica.

Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survival

D. Catovsky, D. Oscier, Z. Davis, 2016, Leukemia and Lymphoma.

The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors

K. Stamatopoulos, R. Rosenquist, Š. Pospíšilová, 2014, British journal of haematology.

Allelic Loss of IRFl in Myelodysplasia and Acute Myeloid Leukemia : Retention of IRFl on the 5 q-Chromosome in Some Patients With the 5 q-Syndrome

D. Oscier, Susan, V. Buckle, 2003 .

The international Prognostic Index for patients with CLL (CLL-IPI) : An international meta-analysis

M. Grever, J. Byrd, D. Neuberg, 2015 .

Common variants at 2q37.3, 8q24.21, 15q21.3, and 16q24.1 influence chronic lymphocytic leukemia risk

E. Campo, E. Montserrat, A. Pettitt, 2010, Nature Genetics.

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

T J Hamblin, D G Oscier, D. Oscier, 1999, Blood.

Assessment of the role of clonogenic B lymphocytes in the pathogenesis of multiple myeloma.

D. Oscier, F. Stevenson, S. Sahota, 1994, Leukemia.

Serous effusions in monocytic leukaemias

D. Oscier, T. Hamblin, G. Mufti, 1984, British journal of haematology.

Circulating stem cell autografts in the treatment of hematologic malignancies

D. Oscier, T. Hamblin, A. Figes, 1988 .

Peripheral blood stem cell autografts in the treatment of lymphoid malignancies: initial experience in three patients

D. Oscier, A. Bell, T. Hamblin, 1987, British journal of haematology.

Cytogenetic, fluorescence in situ hybridisation, and clinical evaluation of translocations with concomitant deletion at 13q14 in chronic lymphocytic leukaemia

D. Oscier, M. Corcoran, A. Gardiner, 1997, Genes, chromosomes & cancer.

Molecular cytogenetic analysis in splenic lymphoma with villous lymphocytes: frequent allelic imbalance of the RB1 gene but not the D13S25 locus on chromosome 13q14.

D. Catovsky, D. Oscier, E. Matutes, 1998, Cancer research.

Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia

D. Oscier, R. Ibbotson, G. Strathdee, 2011, Epigenetics.

TRUE OUTLOOK IN ACUTE MYELOBLASTIC LEUKAEMIA

D. Oscier, T. Hamblin, A. Smith, 1986, The Lancet.

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

J. Gribben, A. Pettitt, W. Gregory, 2009 .

Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors

E. Campo, J. Delgado, K. Stamatopoulos, 2019, Leukemia.

B-cell lymphocytosis survival in early stage chronic lymphocytic leukemia and monoclonal Low frequency mutations independently predict poor treatment free

Parker, D. Oscier, M. Rose-Zerilli, 2015 .

Atypical chronic myeloid leukemias.

D. Oscier, 1997, Pathologie-biologie.

A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027.

W. Ouwehand, R. Marcus, N. Bleehen, 1997, Human gene therapy.

Red cell aplasia in myelodysplastic syndrome.

D. Oscier, T. Hamblin, P. Williamson, 1991, Journal of clinical pathology.

TP53 abnormalities in chronic lymphocytic leukemia exhibit a disease specific profile: meta-analysis of 270 mutations.

A. Pettitt, S. Stilgenbauer, A. Benner, 2008 .

Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion

G. Morgan, D. Catovsky, D. Gonzalez, 2008 .

Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities.

S. Knuutila, G. Gahrton, G. Juliusson, 1990, The New England journal of medicine.

lymphocytic leukemia (letter; comment) Chromosome abnormalities and RB1 gene deletions in chronic

G. Gahrton, G. Juliusson, D. Oscier, 2011 .

Trisomy 12 and structural abnormalities of 13q14 occurring in the same clone in chronic lymphocytic leukaemia

D. Oscier, M. Corcoran, A. Gardiner, 1996, British journal of haematology.

Chromosome abnormalities and RB1 gene deletions in chronic lymphocytic leukemia.

G. Gahrton, G. Juliusson, D. Oscier, 1993, Blood.

The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.

P. Campbell, H. Grallert, A. Green, 2010, Blood.

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

F. Bosch, E. Campo, L. Bullinger, 2022, Leukemia.

Insight into the origin and clonal history of B‐cell tumors as revealed by analysis of immunoglobulin variable region genes

C. Chapman, D. Oscier, T. Hamblin, 1998, Immunological reviews.

The application of X‐chromosome gene probes to the diagnosis of myeloproliferative disease

D. Oscier, A. Jacobs, R. Padua, 1989, British journal of haematology.

HEPARIN‐INDUCED THROMBOCYTOPENIA IN PREGNANCY

D. Oscier, A. Copplestone, 1987, British journal of haematology.

The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre‐mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1

D. Oscier, A. Chase, F. Grand, 2008, Genes, chromosomes & cancer.

Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.

K. Stamatopoulos, T. Sjöblom, D. Rossi, 2016, Blood.

"Stem cell" origin of the hematopoietic defect in dyskeratosis congenita.

T. Dexter, D. Oscier, J. Hows, 1992, Blood.

Fine mapping of the dyskeratosis congenita locus in Xq28.

T. Vulliamy, D. Oscier, G. Forni, 1996, Journal of medical genetics.

5 Myelodysplastic syndromes

D. Oscier, 1987 .

The myelodysplastic syndrome—a practical guide

D. Oscier, J. Wiley, T. Hamblin, 1987, Hematological oncology.

Monocytic skin infiltration in chronic myelomonocytic leukaemia.

G. Mufti, D. Oscier, T. Hamblin, 1986, Clinical and laboratory haematology.

T-chronic lymphocytic leukaemia presenting as primary hypogammaglobulinaemia--evidence of a proliferation of T-suppressor cells.

D. Catovsky, D. Oscier, J. Goldman, 1982, Clinical and experimental immunology.

Myelodysplastic syndromes: a scoring system with prognostic significance

D. Machin, D. Oscier, T. Hamblin, 1985, British journal of haematology.

Immunoreactive calcitonin in leukaemia.

R. Foà, D. Catovsky, D. Oscier, 1979, British medical journal.

Pyogenic abscesses in the myelodysplastic syndrome.

G. Mufti, D. Oscier, T. Hamblin, 1989, BMJ.

The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial

D. Catovsky, D. Oscier, E. Matutes, 2016, British journal of haematology.

Long survival in B‐CLL correlates with surface IgMK phenotype

D. Oscier, T. Hamblin, J. Smith, 1987 .

International scoring system for evaluating prognosis in myelodysplastic syndromes.

T Hamblin, G. Mufti, P. Greenberg, 1997, Blood.

The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1

M. Larrayoz, D. Oscier, G. Packham, 2016, Leukemia.

ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia.

D. Oscier, Z. Davis, M. Corcoran, 2005, Haematologica.

CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes

G. Morgan, D. Catovsky, D. Gonzalez, 2013, Haematologica.

Defining the prognosis of early stage chronic lymphocytic leukaemia patients

Chris Pepper, Aneela Majid, Thet Thet Lin, 2012, British journal of haematology.

(B-CLL) migratory and survival signals in B-cell chronic lymphocytic leukemia ZAP-70 expression is associated with enhanced ability to respond to

S. Richardson, D. Oscier, M. Catherwood, 2011 .

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation

D. Catovsky, R. Wade, D. Oscier, 2010, Haematologica.

Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia – long‐term follow up of patients with different percentages of mutations

D. Oscier, Z. Davis, T. Hamblin, 2008, British journal of haematology.

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

T Hamblin, A. Pettitt, D. Catovsky, 2007, The Lancet.

ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL).

S. Richardson, D. Oscier, M. Catherwood, 2006, Blood.

Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.

D. Oscier, Z. Davis, M. Corcoran, 2002, Blood.

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

D. Oscier, Z. Davis, R. Ibbotson, 2002, Blood.

Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial

T. Stankovic, D. Vavoulis, D. Catovsky, 2020, Leukemia.

Chronic Lymphocytic Leukaemia: Data from the Randomised UK LRF

T. Stankovic, D. Vavoulis, D. Catovsky, 2019 .

Molecular Biology and Cytogenetics of Chronic Lymphocytic Leukemia

D. Oscier, J. Strefford, A. Gardiner, 2013 .

lymphoid tumor cells in vitro and in vivo -deficient ATM The PARP inhibitor olaparib induces significant killing of

M. Dyer, T. Stankovic, P. Moss, 2012 .

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

M. Dyer, T. Stankovic, P. Moss, 2010, Blood.

Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia.

D. Oscier, G. Packham, R. Ibbotson, 2003, Blood.

Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation

L. Pasqualucci, L. Larocca, R. Rabadán, 2011, The Journal of experimental medicine.

Cytogenetic Findings and Survival in B-cell Chronic Lymphocytic Leukemia. Second IWCCLL Compilation of Data on 662 Patients.

P. Nowell, S. Knuutila, G. Gahrton, 1991, Leukemia & lymphoma.

Finemapping ofthedyskeratosis congenita locus inXq28

T. Vulliamy, D. Oscier, S. Knight, 1996 .

Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations

S. Scherer, L. Tsui, D. Oscier, 1999, Oncogene.

Characterization of a t(10;12)(q24;p13) in a case of CML in transformation

R. Aguiar, D. Oscier, J. Goldman, 1997, Genes, chromosomes & cancer.

Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks

Renata Walewska, Christoph Bock, André F. Rendeiro, 2016, Nature Communications.

Recurrent mutations refine prognosis in chronic lymphocytic leukemia

E. Campo, N. Villamor, J. Delgado, 2014, Leukemia.

Male preponderance in chronic lymphocytic leukemia utilizing IGHV 1–69

M. Dyer, D. Oscier, Z. Davis, 2007, Leukemia.

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

A. Pettitt, J. Radford, G. Follows, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia

Terry J. Hamblin, Freda K. Stevenson, D. Oscier, 1999 .

Predictive Biomarkers and Personalized Medicine Functional Analysis of the ATM-p 53-p 21 Pathway in the LRF CLL 4 Trial : Blockade at the Level of p 21 Is Associated with Short Response Duration

A. Pettitt, D. Catovsky, D. Gonzalez, 2012 .

Molecular Cytogenetic Analysis in Splenic Lymphoma with Vifious Lymphocytes : Frequent Allelic Imbalance of the RBJ Gene but not the D 13 S 25 Locus on Chromosome 13 q 141

D. Oscier, E. Matutes, C. Price, 2006 .

13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia

A Collins, T Chaplin, B D Young, 2011, Leukemia.

On 13 q 14 deletions in chronic lymphocytic leukemia

C. Larsson, D. Grandér, D. Oscier, 2008 .

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

A. Pettitt, M. Dyer, K. Stamatopoulos, 2016, Leukemia.

Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia

A. Pettitt, M. Dyer, K. Stamatopoulos, 2015 .

Common ALL with pre-B-cell features showing (8;14) and (14;18) chromosome translocations.

G. Mufti, D. Oscier, T. Hamblin, 1983, Blood.

The consistent 13q14 translocation breakpoint seen in chronic B-cell leukaemia (BCLL) involves deletion of the D13S25 locus which lies distal to the retinoblastoma predisposition gene.

L. Hawthorn, D. Oscier, J. Cowell, 1993, Oncogene.

IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.

W. Klapper, R. Siebert, E. Jaffe, 2018, Blood.

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

P. Abrisqueta, J. Delgado, K. Stamatopoulos, 2019, Blood.

The Genomic and Epigenomic Landscape of Chronic Lymphocytic Leukemia

D. Oscier, J. Strefford, R. Walewska, 2018 .

Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia

C. Yau, S. Knight, C. Holmes, 2012, Leukemia.

Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis

Robert Brown, J. Melo, T. Holyoake, 2007, Clinical Cancer Research.

Distinct organization of the candidate tumor suppressor gene RFP2 in human and mouse: multiple mRNA isoforms in both species- and human-specific antisense transcript RFP2OS.

E. Zabarovsky, A. Baranova, M. Skoblov, 2003, Gene.

Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia.

E. Zabarovsky, G. Gahrton, G. Juliusson, 1998, Blood.

The BCL11 gene family: involvement of BCL11A in lymphoid malignancies.

D G Oscier, D. Steinemann, R. Siebert, 2001, Blood.

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis

R. Greil, E. Montserrat, H. Döhner, 2014, Haematologica.

RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation.

F. McCormick, D. Oscier, A. Jacobs, 1988, Leukemia.

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

D. Oscier, A. Jones, A. Chase, 2005, Blood.

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

D. Oscier, A. Jones, A. Chase, 2005, Blood.

Frequent homozygous deletions of the D13S25 locus in chromosome region 13q14 defines the location of a gene critical in leukaemogenesis in chronic B-cell lymphocytic leukaemia.

L. Hawthorn, D. Oscier, M. Corcoran, 1994, Oncogene.

A cosmid and cDNA fine physical map of a human chromosome 13q14 region frequently lost in B‐cell chronic lymphocytic leukemia and identification of a new putative tumor suppressor gene, Leu5

H. Lehrach, E. Zabarovsky, D. Grandér, 1998, FEBS letters.

Trisomy 12 in B‐cell chronic lymphocytic leukaemia: assessment of lineage restriction by simultaneous analysis of immunophenotype and genotype in interphase cells by fluorescence in situ hybridization

D. Catovsky, E. Matutes, D. Oscier, 1994, British journal of haematology.

RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up

S. Chevret, D. Oscier, T. Pettersson, 1998, Leukemia.

Activation of Ha-ras in human chronic granulocytic and chronic myelomonocytic leukaemia.

D. Oscier, R. Brown, T. Hamblin, 1988, Leukemia research.

Detection of cells of megakaryocyte lineage in haematological malignancies by immuno‐alkaline phosphatase labelling cell smears with a panel of monoclonal antibodies

D. Mason, W. Erber, D. Oscier, 1987, British journal of haematology.

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

A. Hall, D. Oscier, A. Jones, 2008, Blood.

Chromosome abnormalities involving band 13q14 in hematologic malignancies.

M. Seabright, D. Oscier, M. Fitchett, 1987, Cancer genetics and cytogenetics.

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes

G. Mufti, D. Oscier, D. Bowen, 2003, British journal of haematology.

Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2

K. Stamatopoulos, N. Chiorazzi, R. Rosenquist, 2013, Leukemia.

The (epi)genomic landscape of splenic marginal zone lymphoma, biological implications, clinical utility, and future questions

D. Oscier, J. Gibson, J. Strefford, 2021 .

DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy

J. Martín-Subero, A. Queirós, K. Stamatopoulos, 2019, Clinical Epigenetics.

Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia

J. Martín-Subero, K. Stamatopoulos, D. Rossi, 2019, International journal of cancer.

Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation*

M. Larrayoz, D. Oscier, M. Cragg, 2018, Molecular & Cellular Proteomics.

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia

B. Dörken, C. Schmitt, K. Stamatopoulos, 2017, Leukemia.

Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease

W. Tapper, C. Chelala, M. Larrayoz, 2016, Leukemia.

Preview : Published ahead of advance online publication EGR 2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia

B. Dörken, C. Schmitt, K. Stamatopoulos, 2016 .

Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial

D. Catovsky, M. Larrayoz, D. Oscier, 2016, Leukemia.

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

D. Catovsky, D. Oscier, N. Cross, 2013, Blood.

KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype

J. Martinez-Climent, N. Bolli, G. Gundem, 2014, Leukemia.

Chromatin accessibility maps of chronic lymphocytic leukemia identify subtype-specific epigenome signatures and associated transcription regulatory networks

Renata Walewska, Christoph Bock, André F. Rendeiro, 2016 .

Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.

W. Chan, T. Greiner, F. Berger, 2013, Blood.

Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities.

D. Oscier, D. Zhu, F. Stevenson, 1997, Blood.

Correlation of chromosome abnormalities with laboratory features and clinical course in B‐cell chronic lymphocytic leukaemia

D. Oscier, R. Pickering, T. Hamblin, 1990, British journal of haematology.

Chromosomal abnormalities in B-CLL.

D. Oscier, T. Hamblin, M. Fitchett, 1988, Nouvelle revue francaise d'hematologie.

Human Chromosome 7: DNA Sequence and Biology

Junjun Zhang, Nazneen Rahman, Alexander K. Hudek, 2003, Science.

Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome

D. Oscier, M. Corcoran, A. Chase, 2004, Genes, chromosomes & cancer.

An 8;14 translocation in a case of plasma cell leukemia.

D. Oscier, J. Copplestone, S. Johnson, 1987, Leukemia research.

Absence of immunoglobulin and T‐cell receptor gene rearrangements in myelodysplastic syndromes and acute nonlymphocytic leukemias

D. Oscier, C. Summers, S. Pilkington, 1988, American journal of hematology.

cell line HL60 Immunoreactive calcitonin production by a human promyelocytic leukemia

D. Oscier, J. Goldman, I. Macintyre, 2011 .

Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion.

D. Oscier, L. M. Wang, V. Buckle, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome

D. Oscier, V. Buckle, J. Boultwood, 1993 .

Whole Exome Sequencing Identifies Novel Recurrently Mutated Genes in Patients with Splenic Marginal Zone Lymphoma

D. Oscier, Z. Davis, S. Ennis, 2013, PloS one.

Detection of chromosomal 7 loss in myelodysplasia using an extremely polymorphic DNA probe.

A. Jeffreys, D. Oscier, S. Thein, 1988, British Journal of Cancer.

The Genomics of Hairy Cell Leukaemia and Splenic Diffuse Red Pulp Lymphoma

K. Stamatopoulos, D. Oscier, J. Strefford, 2022, Cancers.

Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion

J Boultwood, D. Oscier, F. Ross, 1995, American journal of hematology.

HOMOZYGOUS DELETION OF FMS IN A PATIENT WITH THE 5q— SYNDROME

D. Oscier, V. Buckle, J. Boultwood, 1990, British journal of haematology.

Chronic lymphocytic leukaemia: the nature of the leukaemic cell.

T J Hamblin, D G Oscier, D. Oscier, 1997, Blood reviews.

identification of genetic variants influencing prognosis Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the

S. Richard, D. Catovsky, R. Wade, 2013 .

Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis.

R. Houlston, D. Catovsky, R. Wade, 2008, Blood.

Successful Treatment of Post‐Transfusion Purpura with High Dose Immunoglobulins after Lack of Response to Plasma Exchange

G. Mufti, D. Oscier, T. Hamblin, 1985, Vox sanguinis.

Structure of the granulocyte macrophage colony‐stimulating factor gene in patients with the myelodysplastic syndromes

D. Oscier, V. Buckle, J. Boultwood, 1990, American journal of hematology.

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

R. Siebert, A. Salar, P. Brousset, 2016, Nature Communications.

Exome sequence read depth methods for identifying copy number changes

Andrew Collins, William Tapper, Reuben J. Pengelly, 2015, Briefings Bioinform..

ECTOPIC PRODUCTION OF CALCITONIN AND HYPOCALCAEMIA IN ACUTE LEUKAEMIA

D. Oscier, J. C. Stevenson, 1988, British journal of haematology.

Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity

K. Stamatopoulos, N. Darzentas, R. Rosenquist, 2012, Leukemia.

Absence of the XIST gene from late-replicating isodicentric X chromosomes in leukaemia.

H. Willard, I. Craig, D. Oscier, 1994, Human molecular genetics.

Whole-exome sequencing in relapsing chronic lymphocytic leukemia : clinical impact of recurrent RPS 15 mutations

K. Stamatopoulos, T. Sjöblom, D. Rossi, 2016 .

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

A. Pettitt, H. Döhner, M. Hallek, 2010, Leukemia.

Angiodysplasia of the Colon in Patients with Hemostatic Defects: Risk of Secondary Hemorrhage After Electrocoagulation Treatment

D. Oscier, T. Hamblin, A. J. Bell, 1984, Angiology.

DLEU2 encodes an antisense RNA for the putative bicistronic RFP2/LEU5 gene in humans and mouse

C. Larsson, D. Grandér, D. Oscier, 2004, Genes, chromosomes & cancer.

Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration

A. Pettitt, D. Catovsky, D. Gonzalez, 2012, Clinical Cancer Research.

A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease.

D. Catovsky, D. Oscier, E. Matutes, 2003, Blood.

Immunological abnormalities in myelodysplastic syndromes II. COEXISTENT LYMPHOID OR PLASMA CELL NEOPLASMS: A REPORT OF 20 CASES UNRELATED TO CHEMOTHERAPY

G. Mufti, D. Oscier, T. Hamblin, 1986, British journal of haematology.

A patient with monosomy 7 and polyuria.

D. Oscier, S. Sadullah, M. Armitage, 1992, Leukemia research.

Fludarabine and hemolytic anemia in chronic lymphocytic leukemia.

D. Oscier, J. Orchard, T. Hamblin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

K. Stamatopoulos, R. Rosenquist, D. Oscier, 2015, Clinical Cancer Research.

The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity

D. Catovsky, D. Oscier, Z. Davis, 2016, British journal of haematology.

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria

A. Salar, F. Berger, B. Coiffier, 2008, Leukemia.

DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.

J. Martinez-Climent, L. Cascione, M. Piris, 2015, Blood.

Cytogenetic aberrations and immunoglobulin VH gene mutations in clinically benign CD5- monoclonal B-cell lymphocytosis.

D. Oscier, Z. Davis, Chen Wang, 2007, American journal of clinical pathology.

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

E. Campo, A. Navarro, K. Stamatopoulos, 2020, Blood.

Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma

D. Oscier, S. Ennis, J. Gibson, 2019, Scientific Reports.

Disease‐biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations

D. Tzovaras, K. Stamatopoulos, M. Piris, 2019, The Journal of pathology.

Clonal B-cell lymphocytosis of marginal zone origin.

K. Stamatopoulos, D. Oscier, A. Xochelli, 2017, Best practice & research. Clinical haematology.

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

K. Stamatopoulos, N. Darzentas, T. Shanafelt, 2017, Haematologica.

Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors

E. Campo, A. Navarro, K. Stamatopoulos, 2016, Haematologica.

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Lefteris Angelis, Véronique Giudicelli, Marco Montillo, 2015, Blood.

Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation

E. Meffre, N. Chiorazzi, K. Rai, 2008, Molecular medicine.

Immunoglobulin V genes and CD38 expression in CLL.

T J Hamblin, D G Oscier, D. Oscier, 2000, Blood.

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.

A. Pettitt, M. Pirmohamed, D. Catovsky, 2013, Blood.

The BCL 11 gene family : involvement of BCL 11 A in lymphoid malignancies

D. Steinemann, R. Siebert, M. Dyer, 2001 .

distinct gene expression profile with unmutated immunoglobulin genes , inferior clinical outcome , and ZAP-70 expression identifies a chronic lymphocytic leukemia subtype

L. Staudt, R. Davis, A. Rosenwald, 2003 .

Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12

D. Catovsky, E. Matutes, D. Oscier, 1997, British journal of haematology.

Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL

Caroline L. Wilson, D. Oscier, Shilu Amin, 2012, Journal of cellular and molecular medicine.

The long‐term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years

D. Catovsky, R. Wade, D. Oscier, 2015, British journal of haematology.

Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL.

C. Fegan, D. Oscier, A. Rawstron, 2007 .

Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects

A. Pettitt, D. Oscier, E. Matutes, 2006, Leukemia.

Association between SNP-genotype and chronic lymphocytic leukemia outcome in a randomized chemotherapy trial

R. Houlston, D. Rossi, G. Gaidano, 2011 .

Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia

A. Pettitt, M. Dyer, R. Houlston, 2021, Nature communications.

The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis.

D. Oscier, M. Cragg, T. Hamblin, 2002, Blood.

Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients

F. Bosch, S. Beà, T. Baumann, 2021, Haematologica.

Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival

G. Mufti, D. Oscier, T. Hamblin, 1988, British journal of haematology.

Polyarteritis presenting with thrombocytosis and palliated by plasma exchange.

D. Oscier, T. Hamblin, 1978, Postgraduate medical journal.

Chromosome abnormalities in hairy cell leukaemia variant

D. Catovsky, E. Matutes, D. Oscier, 1994, Genes, chromosomes & cancer.

Chronic lymphocytic leukaemia.

D. Oscier, 1999, British journal of haematology.

Cytogenetic studies in splenic lymphoma with villous lymphocytes

D. Catovsky, E. Matutes, D. Oscier, 1993, British journal of haematology.

Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes

D. Oscier, J. Orchard, S. Bolam, 1997, British journal of haematology.

Splenic marginal-zone lymphoma: ontogeny and genetics

K. Stamatopoulos, D. Oscier, J. Strefford, 2015, Leukemia & lymphoma.

Waldenström's macroglobulinaemia.

D. Oscier, V. Leblond, S. Johnson, 2002, Blood reviews.

The bioavailability of oral fludarabine phosphate is unaffected by food.

D. Oscier, J. Orchard, S. Johnson, 2001, The hematology journal : the official journal of the European Haematology Association.

ABC of clinical haematology: The myelodysplastic syndromes

D. Oscier, 1997, BMJ.

A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.

B. Pégourié, G. Mufti, D. Oscier, 1996, Blood.

RELAPSE AFTER AUTOGRAFTING WITH PERIPHERAL BLOOD STEM CELLS

D. Oscier, T. Hamblin, A. Figes, 1988, The Lancet.

Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia

R. Holder, C. Fegan, G. Mead, 2009, British journal of haematology.

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

J. Gribben, A. Pettitt, G. Follows, 2010 .

Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multicenter study

K. Stamatopoulos, R. Rosenquist, C. Haferlach, 2020, Haematologica.

ERIC multi-center study for the detection of gene mutations in chronic lymphocytic leukemia: an Comparative analysis of targeted next-generation sequencing panels

A. Enjuanes, D. Rossi, R. Rosenquist, 2020 .

Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference

K. Stamatopoulos, R. Rosenquist, Š. Pospíšilová, 2016, Haematologica.

Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?

K. Stamatopoulos, D. Oscier, Z. Davis, 2014, Blood.

Cytogenetic and molecular abnormalities in chronic lymphocytic leukaemia.

D. Oscier, 1994, Blood reviews.

Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis

D. Oscier, N. Cross, M. Rose-Zerilli, 2015, Haematologica.

Novel technique to facilitate the rapid identification of CLL patients utilising the VH3–21 gene

Z A Davis, R E Ibbotson, D G Oscier, 2004, Leukemia.

A multi‐centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphoma

A. Pettitt, M. Dyer, T. Stankovic, 2018, British journal of haematology.

Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation

K. Stamatopoulos, M. Piris, D. Oscier, 2015, Haematologica.

Prognostic Factors in the UK LRF CLL4 Trial.

D. Catovsky, R. Wade, D. Oscier, 2005 .

Reciprocal translocation between chromosomes 8 and 9 in atypical chronic myeloid leukaemia.

G. Mufti, D. Oscier, T. Hamblin, 1985, Journal of medical genetics.

Karyotypic evolution in a granulocytic sarcoma developing in a myeloproliferative disorder with a novel (3;4) translocation

D. Oscier, F. Ross, H. Myint, 1995, British journal of haematology.

Type C TP53‐CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities

W. Tapper, D. Oscier, O. G. Best, 2017, British journal of haematology.

Lymphoid neoplasms.

D. Oscier, A. Gardiner, 2001, Best practice & research. Clinical haematology.

A unique genome in EBV-positive BL.

D. Oscier, J. Strefford, 2019, Blood.

locus in Xq 28 . Fine mapping of the dyskeratosis congenita

T. Vulliamy, D. Oscier, P. Mason, 2022 .

lymphocytic leukemia to Richter syndrome Two main genetic pathways lead to the transformation of chronic

Young, W. Chan, T. Greiner, 2013 .

ZAP-70 by Flow Cytometry: Comparison of Methodologies, and with IgVH Mutational and ZAP-70 Methylation Status.

D. Oscier, O. G. Best, R. Ibbotson, 2005 .

RITUXIMAB PLUS CHLORAMBUCIL (R-CHLORAMBUCIL) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): FINAL ANALYSIS OF AN OPEN-LABEL PHASE II STUDY

J. Gribben, A. Pettitt, G. Follows, 2011 .

Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial

R. Houlston, D. Rossi, G. Gaidano, 2011, Haematologica.

Translocation 1;7 in hematologic disorders--a report of three further cases. Absence of amplification of the gene for the epidermal growth factor receptor.

D. Oscier, V. Buckle, J. Wainscoat, 1991, Cancer genetics and cytogenetics.

Immunoreactive calcitonin production by a human promyelocytic leukemia cell line HL60.

D. Oscier, J. Goldman, I. Macintyre, 1983, Blood.

Use of a retinoblastoma gene probe to investigate clonality in Richter's syndrome.

D. Oscier, T. Hamblin, E. Hodges, 1993, Leukemia.

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

F. Bosch, E. Campo, L. Bullinger, 2021, Blood.

The Natural History of Mutated, Stage AO Chronic Lymphocytic Leukemia.

L. Staudt, A. Wiestner, D. Oscier, 2004 .

congenita "Stem cell" origin of the hematopoietic defect in dyskeratosis

D. Oscier, J. Hows, J. Marsh, 2011 .

HIF-2alpha Associated Familial Erythrocytosis Supports the PHD2-HIF- 2alpha-VHL Axis as the Major Regulator of Erythropoietin Production

A. Green, D. Oscier, M. McMullin, 2008 .

Cytogenetics and molecular genetics of chronic lymphocytic leukaemia.

D. Oscier, 1999, Haematologica.

SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS)

W. Chan, T. Greiner, F. Berger, 2011 .

Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma

Juan F. García, M. Piris, D. Oscier, 2017, Haematologica.

The Composition of the B Cell Receptor Repertoire In 7428 Cases of Chronic Lymphocytic Leukemia: One Third Stereotyped, Two Thirds Heterogeneous - What Does This Mean?

K. Stamatopoulos, N. Darzentas, Nikolaos Laoutaris, 2010 .

Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglogulin Variable Gene: Implications for the Origin and Selection of the Neoplastic Cells

F. Berger, K. Stamatopoulos, M. Piris, 2010 .

CLL: Different ages, dfferent antigen receptor profiles

K. Stamatopoulos, N. Darzentas, N. Chiorazzi, 2013 .

Coexistence of trisomies of chromosomes 12 and 19 in chronic lymphocytic leukemia occurs exclusively in the rare IgG-positive variant

K. Stamatopoulos, G. Juliusson, R. Rosenquist, 2012, Leukemia.

Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia

I. Vlahavas, K. Stamatopoulos, I. Chouvarda, 2014, Immunogenetics.

Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome.

D. Oscier, V. Buckle, J. Boultwood, 1993, Blood.

HEPARIN‐INDUCED THROMBOCYTOPENIA IN PREGNANCY

D. Oscier, A. Copplestone, 1987, British journal of haematology.

Widespread occurrence of the JAK 2 V 617 F mutation in chronic myeloproliferative disorders

D. Oscier, A. Jones, A. Chase, 2005 .

Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

F. Bosch, L. Bullinger, J. Delgado, 2023, Leukemia.

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

E. Montserrat, N. Villamor, H. Johnsen, 2018, Cytometry. Part B, Clinical cytometry.

The JAK2 46/1 Haplotype Predisposes to Myeloproliferative Neoplasms Characterized by Diverse Mutations

P. Campbell, A. Green, S. Schnittger, 2009 .

Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL

D. Oscier, G. Strathdee, G Strathdee, 2006, Leukemia.

A common low penetrance risk allele for chronic lymphocytic leukaemia in the 3’ UTR of IRF4/MUM1 predicts prognosis independent of 1gVH status.

A. Pettitt, R. Houlston, C. Fegan, 2010 .

Ferrokinetic studies and prognosis in aplastic anaemia.

S. Lewis, D. Oscier, D. M. Mccarthy, 1980, Acta haematologica.

Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma

D. Oscier, S. Ennis, J. Strefford, 2019, Scientific Reports.

Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.

T. Lister, D. Oscier, J. Orchard, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inactivation of HOXAGenes by Hypermethylation in Myeloid and LymphoidMalignancy is Frequent and Associated with Poor Prognosis

Robert Brown, J. Melo, T. Holyoake, 2007 .

KLF 2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and 1 identifies a subset with distinct genotype 2 3

J. Climent, N. Bolli, G. Gundem, 2014 .

Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications

K. Stamatopoulos, R. Rosenquist, D. Oscier, 2014 .

gene expression profile unmutated immunoglobulin genes, inferior clinical outcome, and distinct ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with

L. Staudt, R. Davis, A. Rosenwald, 2013 .

Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis.

R. Houlston, D. Catovsky, R. Wade, 2008, Blood.

A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation

R. Gascoyne, W. Klapper, R. Siebert, 2007, Leukemia.

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

D. Catovsky, D. Oscier, N. Cross, 2013, Blood.

Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage

T. Stankovic, C. Fegan, D. Oscier, 2012, Leukemia.

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia

A. Pettitt, C. Fegan, G. Follows, 2012, British journal of haematology.

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.

K. Stamatopoulos, N. Darzentas, Xiao-Jie Yan, 2012, Blood.

Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis.

A. Green, D. Oscier, M. McMullin, 2008, Blood.

Gender as a Prognostic Factor in CLL. Biological Pointers to the Improved Outcome of Women.

D. Catovsky, D. Oscier, E. Matutes, 2004 .

In Chronic Lymphocytic Leukemia Females Survive for Longer Than Males Even in Patients with Unmutated Immunoglobulin Genes.

D. Oscier, R. Ibbotson, J. Orchard, 2004 .

Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Catabolic Chemical Modifications

E. Meffre, N. Chiorazzi, K. Rai, 2008 .

Polyreactive Monoclonal Antibodies Synthesized by Some B-CLL Cells Recognize Specific Antigens on Viable and Apoptotic T Cells.

E. Meffre, N. Chiorazzi, K. Rai, 2006 .

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

J. Gribben, A. Pettitt, G. Follows, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration

A. Pettitt, D. Catovsky, D. Gonzalez, 2012, Clinical Cancer Research.

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL

M. Dyer, T. Stankovic, B. Austen, 2008, Leukemia.

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

M J S Dyer, O G Best, A C Gardiner, 2009, Leukemia.

The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre‐mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1

D. Oscier, A. Chase, F. Grand, 2008, Genes, chromosomes & cancer.

Splenic lymphoma with villous lymphocytes involves B cells with extensively mutated Ig heavy chain variable region genes.

D. Oscier, F. Stevenson, Delin Zhu, 1995, Blood.

The contribution of gene mutations to long-term clinical outcomes: data from the randomised UK LRF CLL4 trial

D. Catovsky, M. Larrayoz, D. Oscier, 2017 .

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

K. Stamatopoulos, D. Lad, T. Chatzikonstantinou, 2023, EClinicalMedicine.

Genetics and Prognostication in Splenic Marginal Zone Lymphoma: 2 Revelations from Deep Sequencing 3 4 Running Title: The clinical significance of gene mutations in SMZL 5

K. Stamatopoulos, D. Oscier, E. Matutes, 2015 .

Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing Running Title: the Clinical Significance of Gene Mutations in Smzl Statement of Translational Relevance

K. Stamatopoulos, R. Rosenquist, D. Oscier, 2022 .

Lack of somatic hypermutation of IG VH genes in lymphoid malignancies with t(2;14)(p13;q32) translocation involving the BCL11A gene

R. Siebert, R. Küppers, L. Harder, 2002, Leukemia.

The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications

K. Stamatopoulos, D. Oscier, J. Strefford, 2024, Exploration of targeted anti-tumor therapy.

Telomere length and DNA methylation epitype both provide independent prognostic information in CLL patients; data from the UK CLL4, ARCTIC and ADMIRE clinical trials.

D. Oscier, J. Strefford, H. Parker, 2024, British journal of haematology.